Global Kidney Fibrosis Treatment Market By Product Type (Angiotensin Converting Enzyme Inhibitors, Pirfenidone, Renin Inhibitors, Angiotensin II Receptor Blockers, Vasopeptidase Inhibitors, and Other Product Types), By End-User (Hospitals, Clinics, and Home Based Treatment), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Report Overview

Global Kidney Fibrosis Treatment Market was valued at US$ 20.6 Billion in 2024 and is expected to grow at a CAGR of 6.1% from 2024 to 2034. In 2024, North America led the market, achieving over 36.8% share with a revenue of US$ 7.6 Billion.

Kidney Fibrosis Treatment Market, Global Analysis, 2020-2024 (US$ Billion)

Kidney fibrosis often results from ongoing inflammation and injury to the kidney tissue. Fibrosis is often considered a pathological feature of advanced CKD. It is a form of maladaptive tissue repair that contributes to the progression of kidney disease. This intricate condition is characterized by the progressive accumulation of fibrous tissue within the renal parenchyma, ultimately concluding in the disruption of kidney structure and function.

The hallmark of kidney fibrosis is the excessive deposition of extracellular matrix proteins, particularly collagen, which forms scar tissue and compromises the kidneys’ ability to filter waste products and maintain fluid and electrolyte balance. When the kidneys are damaged, they may develop fibrosis as part of the repair process, but this scarring can impair their ability to function effectively over time.

• According to NIDDK, Chronic kidney disease (CKD) affects more than 1 out of 7 U.S. adults–a projected 37 billion Americans. For Americans who suffer from high blood pressure or diabetes which are the two main cause of kidney problems, the chance of developing CKD is much higher. Nearly one in three people who suffer from diabetes and one of 5 with high blood pressure suffer from kidney disease.

Key Takeaways

• The global kidney fibrosis treatment market was valued at USD 20.6 billion in 2024 and is anticipated to register substantial growth of USD 37.5 billion by 2034, with 6.1% CAGR.
• The angiotensin converting enzyme inhibitors segment took the lead in the global market, securing 29.1% of the total revenueb share.
• The hospitals segment took the lead in the global market, securing 61.4% of the total revenue share.
• North America maintained its leading position in the global market with a share of over 36.8% of the total revenue.

Product Type Analysis

Angiotensin-converting enzyme inhibitors (ACE inhibitors) have been found to have antifibrotic properties in the kidneys. ACE inhibitor therapy has been shown to slow the progression of kidney diseases which include diabetic nephropathy as well as renal fibrosis. The inhibition of ACE has been proven to reduce the risk of fibrosis in the kidney by reducing mesenchymal transformations associated with DPP-4 and increasing antifibrotic microRNAs.

There is a wealth of evidence that supports the use of ACE inhibitor treatment as the primary mode of care in strategies to preserve renal function in patients suffering from kidney fibrosis. As research continues to advance in the field of renal medicine, ACE inhibitors are likely to remain a vital component of the treatment arsenal for kidney fibrosis patients, offering them hope for a better quality of life and improved renal health.

• According to report published in Nephrology Dialysis Transplantation, a murine model for kidney fibrosis, ACE inhibitors and angiotensin-receptor 1 (AT1) antagonists are found to have an nephroprotective effect and ramipril has been shown to reduce TGFb in addition to CTGF expression more effectively than candesartan in the case of renal fibrosis.

Kidney Fibrosis Treatment Market, Product Type Analysis, 2020-2024 (US$ Billion)

End-User Analysis

The market is fragmented by end-user into hospitals, clinics, and home based treatment. Hospitals dominated the global kidney fibrosis treatment market capturing a significant market share of 61.4% in 2024. Hospitals serve as the primary destination for patients with severe or complex cases of kidney fibrosis, providing comprehensive and specialized care. In hospital settings, patients have access to a wide range of medical professionals, including nephrologists, urologists, surgeons, and other specialists.

This multidisciplinary approach is essential for accurately diagnosing kidney fibrosis, planning surgical interventions if necessary, and managing the condition in a coordinated manner. Hospitals are equipped with advanced diagnostic tools, such as MRI and CT scanners, which are valuable for precise assessment of kidney damage.

Hospitals also play a pivotal role in providing acute care for kidney fibrosis patients experiencing life-threatening complications or kidney failure. They offer dialysis services and are well-prepared to perform kidney transplants when required. Furthermore, hospitals are often centers for cutting-edge research and clinical trials, contributing to advancements in kidney fibrosis treatment.

Kidney Fibrosis Treatment Market, End-User Analysis, 2020-2024 (US$ Billion)

Key Segments Analysis

Product Type

• Angiotensin Converting Enzyme Inhibitors
• Pirfenidone
• Renin Inhibitors
• Angiotensin II Receptor Blockers
• Vasopeptidase Inhibitors
• Other Product Types

End-User

• Hospitals
• Clinics
• Home Based Treatment

Market Dynamics

Increasing Awareness

Increasing awareness plays a significant role in propelling the kidney fibrosis treatment market. This heightened awareness encompasses a broader understanding of kidney fibrosis, its associated symptoms, and the available treatment options among both patients and healthcare professionals. This increased awareness leads to several positive outcomes. Increasing awareness plays a significant role in propelling the kidney fibrosis treatment market.

This heightened awareness encompasses a broader understanding of kidney fibrosis, its associated symptoms, and the available treatment options among both patients and healthcare professionals. Furthermore, greater awareness often results in increased research efforts and funding allocation. A more informed populace means more resources directed towards understanding kidney fibrosis, developing improved treatments, and advancing research in the field.

This, ultimately, leads to the development of more effective medications and therapies, benefiting kidney fibrosis patients and driving the growth of the kidney fibrosis treatment market. In essence, the growing awareness surrounding kidney fibrosis plays a pivotal role in enhancing patient care and promoting research initiatives.

Market Restraints

High Cost of Treatment

Kidney fibrosis, especially in its advanced stages, demands a multifaceted approach to management, including medications, dialysis, and potentially kidney transplantation. Each of these components comes with its own significant financial burden. Pharmaceutical interventions for kidney fibrosis can be costly, with medications needed to manage symptoms, slow disease progression, and control comorbidities.

Dialysis, a lifeline for many patients with end-stage kidney disease, incurs recurring expenses that can be overwhelming. Furthermore, kidney transplantation, while often seen as a long-term solution, carries substantial costs related to the surgical procedure itself, post-transplant care, and immunosuppressive medications necessary to prevent organ rejection.

• According to report published in NCBI, the estimated four-month CKD cost of management varied from US$7725 for stage I to stage II disease up to the sum of US$11,879 in stage V (without RRT) and included high expenses for dialysis and kidney transplantation (US$87,538 and US$124,271, respectively).

Market Opportunities

Advanced Therapeutics

Researchers are exploring the possibility of using genetic engineering to modify or replace malfunctioning genes associated with kidney fibrosis. By precisely altering the genetic makeup of cells involved in fibrotic processes, it may be possible to slow down or even reverse the progression of the disease.

This personalized approach holds great promise for improving treatment outcomes and reducing side effects. Researchers have discovered that a single dosage of gene therapy targeted at kidney cells called podocytes could treat nephrotic syndrome resistant to steroids which is a kind of childhood kidney disease.

• As per the reports published in NCBI, exciting advancements in the field of cell and gene therapy have been reported especially in the field of kidney research which suggests that this type of treatment could be an option for treating kidney disease in the near future.

Another avenue of advanced therapeutics is stem cell therapy. Stem cells have the unique ability to differentiate into various cell types, making them valuable in regenerating damaged kidney tissues. Clinical trials are underway to explore the potential of stem cell transplantation as a means to repair fibrotic kidney tissue and restore renal function. This regenerative medicine approach could revolutionize the treatment of kidney fibrosis by addressing the root cause of the condition.

Impact of macroeconomic factors / Geopolitical factors

Macroeconomic and geopolitical factors significantly impact the global kidney fibrosis treatment market. Macroeconomic conditions, such as economic growth, healthcare spending, and inflation, influence the affordability and availability of treatments. During economic downturns, countries may face budget constraints, limiting healthcare access and impacting the adoption of advanced therapies.

On the other hand, periods of economic prosperity may foster increased investment in healthcare innovations, enhancing the development and accessibility of kidney fibrosis treatments. Geopolitical factors, including political stability, trade relations, and regulatory policies, can also affect market dynamics.

In regions with unstable political environments, the distribution of medical resources may be disrupted, hindering treatment availability. Regulatory policies, like drug approval processes and reimbursement frameworks, differ globally and can either accelerate or delay the entry of new treatments.

Latest Trends

The global kidney fibrosis treatment market is experiencing notable growth, driven by advancements in medical research, increasing awareness of chronic kidney diseases (CKD), and the rising global prevalence of kidney disorders. Kidney fibrosis, a progressive condition often linked with CKD, leads to kidney scarring and impaired function. Key trends shaping the market include the development of targeted therapies aimed at halting or reversing fibrosis, such as anti-fibrotic drugs and gene therapy.

Biologics and small molecules are at the forefront of these innovations. Additionally, the increasing adoption of precision medicine, focusing on individual patient profiles, is further enhancing treatment outcomes. The market is also benefitting from the rise in clinical trials and partnerships between pharmaceutical companies to develop effective treatments.

Regional Analysis

North America’s prominence in the global kidney fibrosis treatment market is driven by several key factors. The region boasts a highly advanced healthcare infrastructure and is a hub for advanced medical research. Moreover, leading pharmaceutical companies, research institutions, and academic centers are fostering an environment of innovation and accelerated development of treatments for kidney fibrosis.

• Esbriet (pirfenidone) is a medication produced by an American company Genentech, Inc. that is used to treat idiopathic pulmonary fibrosis (IPF). The trials have been started to study the effect of Esbriet in the kidney fibrosis treatment.

North America has a notably high prevalence of risk factors linked to kidney fibrosis, notably diabetes and hypertension. The region’s aging population also contributes to a greater incidence of kidney fibrosis, given its higher occurrence in older individuals. This substantial disease burden fuels the demand for effective therapies and drives the kidney fibrosis treatment market in North America.

• According to report of CDC, in 2019, around 1.4 billion new cases of diabetes were diagnosed among people of ages 18 and older. Moreover, the report states that, in the US, more than 130 billion adults are living with diabetes or prediabetes.

Kidney Fibrosis Treatment Market, Regional Analysis, 2020-2024 (US$ Billion)

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Players Analysis

Market share analysis is the process of assessing the percentage of a market controlled by different companies or brands. It helps businesses understand their competitive position and identify growth opportunities.

Companies with higher market share typically have more influence and can leverage economies of scale, while smaller players may focus on niche markets or innovation to grow. Key players in any industry are the companies that hold significant market share or influence. These leaders set trends, dictate pricing strategies, and often drive overall market dynamics.

By analyzing the key players, businesses can assess who the major competitors are, their strengths, weaknesses, strategies, and market positioning. This analysis is crucial for any company aiming to enhance its own market presence, as it offers insights into potential risks and opportunities within the competitive landscape. In essence, it provides a strategic overview of where a company stands relative to its rivals.

Top Key Players

• AstraZeneca plc
• Boehringer Ingelheim International GmbH.
• Fibrogen Inc.
• Genentech
• Alevin Therapeutics Ltd
• Certa Therapeutics
• Apotex Inc.
• Bristol-Myers Squibb Company

Recent Developments

• In September 2024, Boehringer Ingelheim International GmbH announced that the FIBRONEER-IPF trial successfully met its primary endpoint of improving FVC at week 52. The company plans to submit a new drug application for nerandomilast for the treatment of IPF to the FDA and other global regulatory bodies. This positive trial outcome and forthcoming submission will enhance Boehringer Ingelheim’s position in the competitive IPF market and could further expand its respiratory drug portfolio.
• In July 2024, Teva and Sanofi revealed an updated timeline for their anti-TL1A program, duvakitug, a monoclonal antibody targeting TL1A for moderate-to-severe IBD. Advancing this program bolsters both companies’ positions in the IBD treatment market and may lead to the expansion of their immunology portfolios.

Report Scope